Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
| ▸ | PDE4A | P27815 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10973378 | 0.97 | ADORA3 (0.57) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL638929 | 0.94 | ADORA2A (0.53) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL7022545 | 0.76 | ADORA2B (0.57) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL2520260 | 0.76 | ADORA2B (1.00) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL23803929 | 0.75 | ADORA3 (0.49) | ADORA3ADORA2BADORA2AADORA1BLM | |
| SCHEMBL10978398 | 0.74 | PDE4A (0.59) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL9351699 | 0.74 | ADORA2B (0.55) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL10441214 | 0.74 | ADORA2B (0.51) | ADORA3ADORA2BPDE4AADORA2APDE4B | |
| SCHEMBL10981520 | 0.73 | ADORA1 (0.42) | ADORA3ADORA2BADORA2AADORA1BLM | |
| SCHEMBL22560002 | 0.72 | PIK3CD (0.45) | ADORA3ADORA2BBLMPNPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052404-A1 | Pharmaceutical formulations comprising substituted xanthine compounds | SCICLONE PHARMACEUTICALS, INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1448203-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS | Sciclone Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003037345-A9 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003037345-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING SUBSTITUTED XANTHINE COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| US-4644001-A | BRONCHODILATOR, CARDIOTONIC AGENTS | AKTIEBOLAGET DRACO (SE) | 1987-02-17 | — | — | US | disclosed |
| US-4548818-A | Composition and methods for the treatment of chronic obstructive airway disease and cardiac disease using 3-alkylxanthines | AKTEBOLAGET DRACO, A COMPANY OF SWEDEN (SE) | 1985-10-22 | — | — | US | disclosed |
| EP-0010531-B1 | 3-ALKYLXANTHINES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS FOR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAY DISEASE AND CARDIAC DISEASE | Aktiebolaget DRACO (SE) | 1982-06-02 | — | — | EP | disclosed |
| EP-0010531-A1 | 3-Alkylxanthines, processes for their preparation and compositions for use in the treatment of chronic obstructive airway disease and cardiac disease | Aktiebolaget DRACO (SE) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052404-A1 | Pharmaceutical formulations comprising substituted xanthine compounds | CFTR, XDH, SLC10A1 | ADORA3 139/4885ADORA2B 325/4885PDE4A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.